LB Pharmaceuticals, Inc. (LBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$49.34+3.83%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LBRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -6.9% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
LBRX — CFO transition
Dated 2026-09-03
CFO — Joseph M. Miller: The filing announces the appointment of an external candidate as CFO, which is a new hire rather than a departure of a sitting executive.
Why it matters: Adding to the pipeline may bring new treatments and money for LB Pharmaceuticals.
Supportive ifThe company shows new ways to use LB-102. It can help treat Alzheimer's disease psychosis.
Worry ifNo new uses or updates were shared, even though they promised them before.
Why it matters: Changes in leadership can affect how clinical trials run. Stability is important during trials.
Watch forNew leaders help stabilize the executive team. They keep focus on clinical trials.
Also watch forMore changes in leadership can slow down clinical trials or change plans.
Why it matters: Successful fundraising can help the company. It supports operations and growth.
Supportive ifA successful private placement raised more than $10 million.
Worry ifFailure to secure funding or delays in capital raising efforts.
Why it matters: Advancing clinical trials helps LB Pharmaceuticals earn trust. It also helps them get approvals.
Supportive ifA press release shares good trial results or new regulatory filings.
Worry ifNo news on clinical trials or delays in regulatory filings.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$189 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $578 loss on $10,000 · 5.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,782 loss on $10,000 · 17.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Expanding the pipeline could lead to new treatments and revenue streams. This is crucial for the company's growth.
Supportive ifManagement shares new uses for LB-102. It can help with negative symptoms of schizophrenia.
Worry ifNo new indications are announced or progress is stalled.
Why it matters: Trends in net loss will show how well the company is doing as it grows.
Worry ifNet loss goes down each quarter, showing better financial health.
Less concerning ifNet loss goes up or stays high, showing ongoing money problems.
Why it matters: This meeting shows trust in LB-102's data and its chances for approval.
Supportive ifThe company announces a scheduled pre-NDA meeting with the FDA for LB-102.
Worry ifNo pre-NDA meeting was announced, even with good topline data.
Why it matters: Trial results will show LB-102's potential for bipolar depression. This affects future plans.
Supportive ifThe ILLUMINATE-1 trial shows that LB-102 works for bipolar depression.
Worry ifThe ILLUMINATE-1 trial shows LB-102 does not work for bipolar depression.
Why it matters: Updates on cash runway will show if the company can pay for its projects.
Supportive ifManagement says cash runway lasts until Q2 2029. This helps fund clinical trials.
Worry ifManagement says cash runway is shorter than expected. This raises funding worries.
Why it matters: Data from this trial will show if LB-102 helps with bipolar depression. This affects its market potential.
Supportive ifTopline data from the Phase 2 trial of LB-102 in bipolar depression is reported in the first quarter of 2028.
Worry ifData from the trial is delayed beyond the first quarter of 2028.
Why it matters: Topline data will show if LB-102 works for schizophrenia. This may affect future plans and investor trust.
Supportive ifTopline results from the NOVA-2 trial are reported in the first half of 2027.
Worry ifTopline results are delayed beyond the first half of 2027.
Why it matters: Stable leadership helps the company focus on clinical work and plans.
Supportive ifManagement announces new hires. They strengthen the leadership team and support projects.
Worry ifMore leadership changes create instability. They distract from clinical goals.
Why it matters: This funding is key for LB-102's clinical trials and pipeline growth.
Supportive ifThe private placement will close around July 30, 2026.
Worry ifThe private placement does not close as planned or faces significant delays.
Why it matters: The new CMO will shape the company's future drug development and strategy.
Watch forA press release says there is a new Chief Medical Officer. This person has good industry experience.
Also watch forNo new CMO is appointed by the next earnings date on August 13, 2026.
Why it matters: If revenue growth goes up, it could help LB Pharmaceuticals.
Supportive ifHealth Care sector revenue growth speeds up to over 10% year over year.
Worry ifSector revenue growth keeps slowing down to below 10% year over year.
Why it matters: This data is key for LB-102's approval and market launch. Good results could lead to big growth.
Supportive ifTopline data from the NOVA-2 trial shows good results for LB-102's effectiveness and safety.
Worry ifThe NOVA-2 trial data shows no effectiveness or safety. This causes delays.